Fisher Asset Management LLC Sells 769 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fisher Asset Management LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,913 shares of the biopharmaceutical company’s stock after selling 769 shares during the quarter. Fisher Asset Management LLC’s holdings in Gilead Sciences were worth $1,046,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of the company. Tompkins Financial Corp grew its position in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. OFI Invest Asset Management acquired a new stake in Gilead Sciences in the 3rd quarter worth $26,000. Fortitude Family Office LLC acquired a new stake in Gilead Sciences in the 4th quarter worth $29,000. Rakuten Securities Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth $33,000. Finally, Financial Connections Group Inc. acquired a new stake in Gilead Sciences in the 4th quarter worth $40,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $64.58 on Friday. The firm has a market cap of $80.41 billion, a PE ratio of 179.39, a price-to-earnings-growth ratio of 1.31 and a beta of 0.22. Gilead Sciences, Inc. has a 12 month low of $64.33 and a 12 month high of $87.86. The company has a quick ratio of 0.72, a current ratio of 0.98 and a debt-to-equity ratio of 1.08. The company’s 50-day moving average price is $70.09 and its two-hundred day moving average price is $75.52.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. During the same period in the previous year, the firm posted $1.37 earnings per share. The company’s revenue was up 5.3% on a year-over-year basis. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 3.74 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.77%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Morgan Stanley decreased their price target on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Friday, April 26th. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a research report on Wednesday, April 24th. Truist Financial lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the company from $91.00 to $82.00 in a research report on Thursday, February 22nd. Wells Fargo & Company decreased their target price on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Finally, Cantor Fitzgerald decreased their target price on shares of Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Eleven equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has an average rating of “Hold” and a consensus target price of $83.69.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.29% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.